_id
69148a7fccc777a4e85d9913
Ticker
PBM
Name
Psyence Biomedical Ltd. Common Shares
Exchange
NASDAQ
Address
121 Richmond Street West, Toronto, ON, Canada, M5H2K1
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.psyencebiomed.com
Description
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company has a strategic collaboration with PsyLabs to produce Ibogaine. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
Last Close
0.82
Volume
692269
Current Price
0.7947
Change
-0.0734
Last Updated
2026-01-06T08:54:50.196Z
Image
data:image/webp;base64,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
Ipo Date
2024-01-25T00:00:00.000Z
Market Cap
1495768
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.9923333333333333
Sentiment Sources
3
Current Quarter
2025-09-30
Revenue
0
Cost Of Revenue
1330
Gross Profit
-1330
Operating Expenses
1504977
Operating Income
-1506307
Interest Expense
2753
Pretax Income
-753254
Net Income
-753254
Eps
-0.5084308284627955
Dividends Per Share
-
Shares Outstanding
1872051
Income Tax Expense
-
EBITDA
-749168
Operating Margin
-
Total Other Income Expense Net
753053
Cash
7197176
Short Term Investments
-
Receivables
174187
Inventories
-
Total Current Assets
7629455
Property Plant Equipment
8690
Total Assets
12810145
Payables
235868
Short Term Debt
-
Long Term Debt
-
Total Liabilities
943068
Equity
11867077
Bs_currency_symbol
USD
Depreciation
1330
Change In Working Capital
-
Cash From Operations
-
Capital Expenditures
0
Cash From Investing
-
Cash From Financing
-
Net Change In Cash
-
Cf_currency_symbol
USD
PE
-
PB
0.09921310082508102
ROE
-6.3474265819628535
ROA
-5.88013640751139
FCF
-
Fcf Percent
-
Piotroski FScore
0
Health Score
41
Deep Value Investing Score
6.5
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
4.3
Garp Investing Score
2
Growth Investing Score
1
Momentum Investing Score
5
Net Net Investing Score
8
Quality Investing Score
2.5
Value Investing Score
6.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
0
Quarters > 0 > income Statement > cost Of Revenue
1330
Quarters > 0 > income Statement > gross Profit
-1330
Quarters > 0 > income Statement > operating Expenses
1504977
Quarters > 0 > income Statement > operating Income
-1506307
Quarters > 0 > income Statement > interest Expense
2753
Quarters > 0 > income Statement > pretax Income
-753254
Quarters > 0 > income Statement > net Income
-753254
Quarters > 0 > income Statement > eps
-0.5084308284627955
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
1481527
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-749168
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
753053
Quarters > 0 > income Statement > currency_symbol
USD
Quarters > 0 > balance Sheet > cash
7197176
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
174187
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
7629455
Quarters > 0 > balance Sheet > property Plant Equipment
8690
Quarters > 0 > balance Sheet > total Assets
12810145
Quarters > 0 > balance Sheet > payables
235868
Quarters > 0 > balance Sheet > short Term Debt
-
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
943068
Quarters > 0 > balance Sheet > equity
11867077
Quarters > 0 > balance Sheet > currency_symbol
USD
Quarters > 0 > cash Flow > net Income
-753254
Quarters > 0 > cash Flow > depreciation
1330
Quarters > 0 > cash Flow > change In Working Capital
-
Quarters > 0 > cash Flow > cash From Operations
-
Quarters > 0 > cash Flow > capital Expenditures
0
Quarters > 0 > cash Flow > cash From Investing
-
Quarters > 0 > cash Flow > cash From Financing
-
Quarters > 0 > cash Flow > net Change In Cash
-
Quarters > 0 > cash Flow > currency_symbol
USD
Quarters > 0 > ratios > PE
-0.5084308284627955
Quarters > 0 > ratios > PB
0.09921310082508102
Quarters > 0 > ratios > ROE
-6.3474265819628535
Quarters > 0 > ratios > ROA
-5.88013640751139
Quarters > 0 > ratios > FCF
-
Quarters > 0 > ratios > Piotroski FScore
0
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
41
Quarters > 1 > quarter
2024-12-31
Quarters > 1 > income Statement > revenue
-
Quarters > 1 > income Statement > cost Of Revenue
1016
Quarters > 1 > income Statement > gross Profit
-1016
Quarters > 1 > income Statement > operating Expenses
1157118
Quarters > 1 > income Statement > operating Income
-1157118
Quarters > 1 > income Statement > interest Expense
3715
Quarters > 1 > income Statement > pretax Income
141473
Quarters > 1 > income Statement > net Income
141473
Quarters > 1 > income Statement > eps
0.5112237744548918
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
276734
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
146204
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
1298591
Quarters > 1 > income Statement > currency_symbol
-
Quarters > 1 > balance Sheet > cash
1932519
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
125080
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
2243372
Quarters > 1 > balance Sheet > property Plant Equipment
10126
Quarters > 1 > balance Sheet > total Assets
2253498
Quarters > 1 > balance Sheet > payables
805613
Quarters > 1 > balance Sheet > short Term Debt
2500862
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
3508604
Quarters > 1 > balance Sheet > equity
-1255106
Quarters > 1 > balance Sheet > currency_symbol
-
Quarters > 1 > cash Flow > net Income
-
Quarters > 1 > cash Flow > depreciation
1016
Quarters > 1 > cash Flow > change In Working Capital
-
Quarters > 1 > cash Flow > cash From Operations
-
Quarters > 1 > cash Flow > capital Expenditures
-
Quarters > 1 > cash Flow > cash From Investing
-
Quarters > 1 > cash Flow > cash From Financing
-
Quarters > 1 > cash Flow > net Change In Cash
-
Quarters > 1 > cash Flow > currency_symbol
-
Quarters > 1 > ratios > PE
0.5112237744548918
Quarters > 1 > ratios > PB
-0.1752206664616375
Quarters > 1 > ratios > ROE
-11.271796963762423
Quarters > 1 > ratios > ROA
6.2779288022443325
Quarters > 1 > ratios > FCF
-
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
43
Quarters > 2 > quarter
2024-09-30
Quarters > 2 > income Statement > revenue
0
Quarters > 2 > income Statement > cost Of Revenue
-
Quarters > 2 > income Statement > gross Profit
-
Quarters > 2 > income Statement > operating Expenses
1157118
Quarters > 2 > income Statement > operating Income
-1157118
Quarters > 2 > income Statement > interest Expense
3715
Quarters > 2 > income Statement > pretax Income
141473
Quarters > 2 > income Statement > net Income
141473
Quarters > 2 > income Statement > eps
1.8612909167456058
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
76008
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
1302306
Quarters > 2 > income Statement > currency_symbol
USD
Quarters > 2 > balance Sheet > cash
1932519
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
-
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
2243372
Quarters > 2 > balance Sheet > property Plant Equipment
10126
Quarters > 2 > balance Sheet > total Assets
2253498
Quarters > 2 > balance Sheet > payables
805613
Quarters > 2 > balance Sheet > short Term Debt
-
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
3508604
Quarters > 2 > balance Sheet > equity
-1255106
Quarters > 2 > balance Sheet > currency_symbol
USD
Quarters > 2 > cash Flow > net Income
141473
Quarters > 2 > cash Flow > depreciation
-
Quarters > 2 > cash Flow > change In Working Capital
-
Quarters > 2 > cash Flow > cash From Operations
-
Quarters > 2 > cash Flow > capital Expenditures
0
Quarters > 2 > cash Flow > cash From Investing
-
Quarters > 2 > cash Flow > cash From Financing
-
Quarters > 2 > cash Flow > net Change In Cash
-
Quarters > 2 > cash Flow > currency_symbol
USD
Quarters > 2 > ratios > PE
1.8612909167456058
Quarters > 2 > ratios > PB
-0.04812625993342395
Quarters > 2 > ratios > ROE
-11.271796963762423
Quarters > 2 > ratios > ROA
6.2779288022443325
Quarters > 2 > ratios > FCF
-
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
43
Quarters > 3 > quarter
2023-12-31
Quarters > 3 > income Statement > revenue
-
Quarters > 3 > income Statement > cost Of Revenue
-
Quarters > 3 > income Statement > gross Profit
-
Quarters > 3 > income Statement > operating Expenses
632103
Quarters > 3 > income Statement > operating Income
-632103
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-24763242
Quarters > 3 > income Statement > net Income
-24763242
Quarters > 3 > income Statement > eps
-1.8492922566394978
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
13390659
Quarters > 3 > income Statement > income Tax Expense
-118
Quarters > 3 > income Statement > EBITDA
-632101
Quarters > 3 > income Statement > operating Margin
-
Quarters > 3 > income Statement > total Other Income Expense Net
-24131139
Quarters > 3 > income Statement > currency_symbol
-
Quarters > 3 > balance Sheet > cash
733.19
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
-
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
1126
Quarters > 3 > balance Sheet > property Plant Equipment
5.49
Quarters > 3 > balance Sheet > total Assets
1132
Quarters > 3 > balance Sheet > payables
562.35
Quarters > 3 > balance Sheet > short Term Debt
10447
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
12104
Quarters > 3 > balance Sheet > equity
-10972
Quarters > 3 > balance Sheet > currency_symbol
-
Quarters > 3 > cash Flow > net Income
-24763
Quarters > 3 > cash Flow > depreciation
0.12
Quarters > 3 > cash Flow > change In Working Capital
-167
Quarters > 3 > cash Flow > cash From Operations
-662
Quarters > 3 > cash Flow > capital Expenditures
2.86
Quarters > 3 > cash Flow > cash From Investing
-2.86
Quarters > 3 > cash Flow > cash From Financing
738.34
Quarters > 3 > cash Flow > net Change In Cash
73.2
Quarters > 3 > cash Flow > currency_symbol
-
Quarters > 3 > ratios > PE
-1.8492922566394978
Quarters > 3 > ratios > PB
-969.8830393091506
Quarters > 3 > ratios > ROE
225694.8778709442
Quarters > 3 > ratios > ROA
-2187565.5477031805
Quarters > 3 > ratios > FCF
-664.86
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-
Quarters > 3 > health Score
39
Annuals > 0 > quarter
2025-03-31
Annuals > 0 > income Statement > revenue
0
Annuals > 0 > income Statement > cost Of Revenue
4268
Annuals > 0 > income Statement > gross Profit
-4268
Annuals > 0 > income Statement > operating Expenses
3658755
Annuals > 0 > income Statement > operating Income
-3663023
Annuals > 0 > income Statement > interest Expense
9270
Annuals > 0 > income Statement > pretax Income
1011790
Annuals > 0 > income Statement > net Income
1011790
Annuals > 0 > income Statement > eps
1.781263974028992
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
568018
Annuals > 0 > income Statement > income Tax Expense
-
Annuals > 0 > income Statement > EBITDA
1025324
Annuals > 0 > income Statement > operating Margin
-
Annuals > 0 > income Statement > total Other Income Expense Net
4674813
Annuals > 0 > income Statement > currency_symbol
USD
Annuals > 0 > balance Sheet > cash
6135166
Annuals > 0 > balance Sheet > short Term Investments
-
Annuals > 0 > balance Sheet > receivables
137348
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
6560274
Annuals > 0 > balance Sheet > property Plant Equipment
11096
Annuals > 0 > balance Sheet > total Assets
7316370
Annuals > 0 > balance Sheet > payables
261937
Annuals > 0 > balance Sheet > short Term Debt
-
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
594366
Annuals > 0 > balance Sheet > equity
6722004
Annuals > 0 > balance Sheet > currency_symbol
USD
Annuals > 0 > cash Flow > net Income
1011790
Annuals > 0 > cash Flow > depreciation
4268
Annuals > 0 > cash Flow > change In Working Capital
-386203
Annuals > 0 > cash Flow > cash From Operations
-3734238
Annuals > 0 > cash Flow > capital Expenditures
9877
Annuals > 0 > cash Flow > cash From Investing
-16230
Annuals > 0 > cash Flow > cash From Financing
9152446
Annuals > 0 > cash Flow > net Change In Cash
5401978
Annuals > 0 > cash Flow > currency_symbol
USD
Annuals > 0 > ratios > PE
1.781263974028992
Annuals > 0 > ratios > PB
0.06131413501092829
Annuals > 0 > ratios > ROE
15.051910114900258
Annuals > 0 > ratios > ROA
13.829125645641213
Annuals > 0 > ratios > FCF
-3744115
Annuals > 0 > ratios > Piotroski FScore
2
Annuals > 0 > ratios > fcf Percent
-
Annuals > 0 > health Score
70
Annuals > 1 > quarter
2024-03-31
Annuals > 1 > income Statement > revenue
0
Annuals > 1 > income Statement > cost Of Revenue
240
Annuals > 1 > income Statement > gross Profit
-240
Annuals > 1 > income Statement > operating Expenses
2751585
Annuals > 1 > income Statement > operating Income
-2751825
Annuals > 1 > income Statement > interest Expense
52941
Annuals > 1 > income Statement > pretax Income
-51159048
Annuals > 1 > income Statement > net Income
-51159048
Annuals > 1 > income Statement > eps
-7.849832789005733
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
6517215
Annuals > 1 > income Statement > income Tax Expense
-
Annuals > 1 > income Statement > EBITDA
-51105872
Annuals > 1 > income Statement > operating Margin
-
Annuals > 1 > income Statement > total Other Income Expense Net
-48407223
Annuals > 1 > income Statement > currency_symbol
USD
Annuals > 1 > balance Sheet > cash
762799
Annuals > 1 > balance Sheet > short Term Investments
-29611
Annuals > 1 > balance Sheet > receivables
41747
Annuals > 1 > balance Sheet > inventories
-29611
Annuals > 1 > balance Sheet > total Current Assets
1126672
Annuals > 1 > balance Sheet > property Plant Equipment
5487
Annuals > 1 > balance Sheet > total Assets
1132159
Annuals > 1 > balance Sheet > payables
562352
Annuals > 1 > balance Sheet > short Term Debt
10447889
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
12104699
Annuals > 1 > balance Sheet > equity
-10972540
Annuals > 1 > balance Sheet > currency_symbol
USD
Annuals > 1 > cash Flow > net Income
-51159048
Annuals > 1 > cash Flow > depreciation
240
Annuals > 1 > cash Flow > change In Working Capital
-1172951
Annuals > 1 > cash Flow > cash From Operations
-2945367
Annuals > 1 > cash Flow > capital Expenditures
5727
Annuals > 1 > cash Flow > cash From Investing
-5727
Annuals > 1 > cash Flow > cash From Financing
2350000
Annuals > 1 > cash Flow > net Change In Cash
-601092
Annuals > 1 > cash Flow > currency_symbol
USD
Annuals > 1 > ratios > PE
-7.849832789005733
Annuals > 1 > ratios > PB
-0.4309750708587073
Annuals > 1 > ratios > ROE
466.24617454117276
Annuals > 1 > ratios > ROA
-4518.715834083376
Annuals > 1 > ratios > FCF
-2951094
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-
Annuals > 1 > health Score
30
Annuals > 2 > quarter
2023-03-31
Annuals > 2 > income Statement > revenue
0
Annuals > 2 > income Statement > cost Of Revenue
-
Annuals > 2 > income Statement > gross Profit
-
Annuals > 2 > income Statement > operating Expenses
1293977
Annuals > 2 > income Statement > operating Income
-1293980
Annuals > 2 > income Statement > interest Expense
0
Annuals > 2 > income Statement > pretax Income
8014314
Annuals > 2 > income Statement > net Income
8014314
Annuals > 2 > income Statement > eps
0.24527358057455487
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
32674999
Annuals > 2 > income Statement > income Tax Expense
-
Annuals > 2 > income Statement > EBITDA
-1293980
Annuals > 2 > income Statement > operating Margin
-
Annuals > 2 > income Statement > total Other Income Expense Net
9308294
Annuals > 2 > income Statement > currency_symbol
CAD
Annuals > 2 > balance Sheet > cash
128677
Annuals > 2 > balance Sheet > short Term Investments
-
Annuals > 2 > balance Sheet > receivables
60898
Annuals > 2 > balance Sheet > inventories
1
Annuals > 2 > balance Sheet > total Current Assets
1205712
Annuals > 2 > balance Sheet > property Plant Equipment
0
Annuals > 2 > balance Sheet > total Assets
258931116
Annuals > 2 > balance Sheet > payables
1628143
Annuals > 2 > balance Sheet > short Term Debt
685000
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
14271212
Annuals > 2 > balance Sheet > equity
244659905
Annuals > 2 > balance Sheet > currency_symbol
CAD
Annuals > 2 > cash Flow > net Income
-24489
Annuals > 2 > cash Flow > depreciation
0
Annuals > 2 > cash Flow > change In Working Capital
-54437
Annuals > 2 > cash Flow > cash From Operations
-519603
Annuals > 2 > cash Flow > capital Expenditures
0
Annuals > 2 > cash Flow > cash From Investing
-
Annuals > 2 > cash Flow > cash From Financing
1172923
Annuals > 2 > cash Flow > net Change In Cash
-519605
Annuals > 2 > cash Flow > currency_symbol
USD
Annuals > 2 > ratios > PE
0.24527358057455487
Annuals > 2 > ratios > PB
0.09690586315890215
Annuals > 2 > ratios > ROE
3.2756957050236735
Annuals > 2 > ratios > ROA
3.0951529209027164
Annuals > 2 > ratios > FCF
-519603
Annuals > 2 > ratios > Piotroski FScore
2
Annuals > 2 > ratios > fcf Percent
-
Annuals > 2 > health Score
54
Annuals > 3 > quarter
2022-03-31
Annuals > 3 > income Statement > revenue
0
Annuals > 3 > income Statement > cost Of Revenue
-
Annuals > 3 > income Statement > gross Profit
-
Annuals > 3 > income Statement > operating Expenses
334288
Annuals > 3 > income Statement > operating Income
-334290
Annuals > 3 > income Statement > interest Expense
-
Annuals > 3 > income Statement > pretax Income
8230440
Annuals > 3 > income Statement > net Income
8230440
Annuals > 3 > income Statement > eps
0.2518879954671154
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
32674999
Annuals > 3 > income Statement > income Tax Expense
-
Annuals > 3 > income Statement > EBITDA
-334290
Annuals > 3 > income Statement > operating Margin
-
Annuals > 3 > income Statement > total Other Income Expense Net
8564730
Annuals > 3 > income Statement > currency_symbol
CAD
Annuals > 3 > balance Sheet > cash
648282
Annuals > 3 > balance Sheet > short Term Investments
-
Annuals > 3 > balance Sheet > receivables
39546
Annuals > 3 > balance Sheet > inventories
-39546
Annuals > 3 > balance Sheet > total Current Assets
797196
Annuals > 3 > balance Sheet > property Plant Equipment
-
Annuals > 3 > balance Sheet > total Assets
256224293
Annuals > 3 > balance Sheet > payables
36888
Annuals > 3 > balance Sheet > short Term Debt
-
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
19578702
Annuals > 3 > balance Sheet > equity
236645591
Annuals > 3 > balance Sheet > currency_symbol
CAD
Annuals > 3 > cash Flow > net Income
-1858234
Annuals > 3 > cash Flow > depreciation
-
Annuals > 3 > cash Flow > change In Working Capital
129744
Annuals > 3 > cash Flow > cash From Operations
-1396421
Annuals > 3 > cash Flow > capital Expenditures
0
Annuals > 3 > cash Flow > cash From Investing
-32039
Annuals > 3 > cash Flow > cash From Financing
-1627576
Annuals > 3 > cash Flow > net Change In Cash
-3056037
Annuals > 3 > cash Flow > currency_symbol
CAD
Annuals > 3 > ratios > PE
0.2518879954671154
Annuals > 3 > ratios > PB
0.10018770759350425
Annuals > 3 > ratios > ROE
3.477960423948909
Annuals > 3 > ratios > ROA
3.2122012724218933
Annuals > 3 > ratios > FCF
-1396421
Annuals > 3 > ratios > Piotroski FScore
2
Annuals > 3 > ratios > fcf Percent
-
Annuals > 3 > health Score
54
Valuation > metrics > PE
-0.5084308284627955
Valuation > metrics > PB
0.09921310082508102
Valuation > final Score
70
Valuation > verdict
90.1% Undervalued
Profitability > metrics > ROE
-6.3474265819628535
Profitability > metrics > ROA
-9.872972577988861
Profitability > final Score
15
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.0794692745315464
Risk > metrics > Interest Coverage
-547.1511078823102
Risk > final Score
-2129
Risk > verdict
High
Liquidity > metrics > Current Ratio
32.346291145895165
Liquidity > metrics > Quick Ratio
32.346291145895165
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
70
Prev Valuations > 1
70
Prev Valuations > 2
50
Prev Profitabilities > 0
34
Prev Profitabilities > 1
34
Prev Profitabilities > 2
55
Prev Risks > 0
-1216
Prev Risks > 1
-1216
Prev Risks > 2
30
Prev Liquidities > 0
44
Prev Liquidities > 1
100
Prev Liquidities > 2
15
Updated At
2026-01-20T22:22:25.740Z
Earnings History > 0 > period
2025-09-30
Earnings History > 0 > report Date
2025-11-20
Earnings History > 0 > date
2025-09-30
Earnings History > 0 > before After Market
-
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-0.51
Earnings History > 0 > eps Estimate
0
Earnings History > 0 > eps Difference
-0.51
Earnings History > 0 > surprise Percent
-
Earnings History > 1 > period
2025-03-31
Earnings History > 1 > report Date
2025-06-25
Earnings History > 1 > date
2025-03-31
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
-99.97
Earnings History > 1 > eps Estimate
0
Earnings History > 1 > eps Difference
-99.97
Earnings History > 1 > surprise Percent
-
Earnings History > 2 > period
2024-12-31
Earnings History > 2 > report Date
2025-01-23
Earnings History > 2 > date
2024-12-31
Earnings History > 2 > before After Market
-
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
4.06
Earnings History > 2 > eps Estimate
0
Earnings History > 2 > eps Difference
4.06
Earnings History > 2 > surprise Percent
-
Earnings History > 3 > period
2024-09-30
Earnings History > 3 > report Date
2024-09-30
Earnings History > 3 > date
2024-09-30
Earnings History > 3 > before After Market
-
Earnings History > 3 > currency
-
Earnings History > 3 > eps Actual
4.0733
Earnings History > 3 > eps Estimate
-
Earnings History > 3 > eps Difference
0
Earnings History > 3 > surprise Percent
-
Earnings History > 4 > period
2023-09-30
Earnings History > 4 > report Date
2023-09-30
Earnings History > 4 > date
2023-09-30
Earnings History > 4 > before After Market
-
Earnings History > 4 > currency
USD
Earnings History > 4 > eps Actual
-50.3213
Earnings History > 4 > eps Estimate
-
Earnings History > 4 > eps Difference
0
Earnings History > 4 > surprise Percent
-
Earnings History > 5 > period
2023-06-30
Earnings History > 5 > report Date
2023-06-30
Earnings History > 5 > date
2023-06-30
Earnings History > 5 > before After Market
-
Earnings History > 5 > currency
USD
Earnings History > 5 > eps Actual
-4.6736
Earnings History > 5 > eps Estimate
-
Earnings History > 5 > eps Difference
0
Earnings History > 5 > surprise Percent
-
Earnings History > 6 > period
2023-03-31
Earnings History > 6 > report Date
2023-03-31
Earnings History > 6 > date
2023-03-31
Earnings History > 6 > before After Market
-
Earnings History > 6 > currency
USD
Earnings History > 6 > eps Actual
-1.2805
Earnings History > 6 > eps Estimate
-
Earnings History > 6 > eps Difference
0
Earnings History > 6 > surprise Percent
-
Earnings History > 7 > period
2022-12-31
Earnings History > 7 > report Date
2023-03-23
Earnings History > 7 > date
2022-12-31
Earnings History > 7 > before After Market
-
Earnings History > 7 > currency
USD
Earnings History > 7 > eps Actual
0.05
Earnings History > 7 > eps Estimate
-
Earnings History > 7 > eps Difference
0
Earnings History > 7 > surprise Percent
-
Earnings History > 8 > period
2022-09-30
Earnings History > 8 > report Date
2022-11-14
Earnings History > 8 > date
2022-09-30
Earnings History > 8 > before After Market
-
Earnings History > 8 > currency
USD
Earnings History > 8 > eps Actual
0.03
Earnings History > 8 > eps Estimate
-
Earnings History > 8 > eps Difference
0
Earnings History > 8 > surprise Percent
-
Earnings History > 9 > period
2022-06-30
Earnings History > 9 > report Date
2022-08-15
Earnings History > 9 > date
2022-06-30
Earnings History > 9 > before After Market
-
Earnings History > 9 > currency
USD
Earnings History > 9 > eps Actual
0.07
Earnings History > 9 > eps Estimate
-
Earnings History > 9 > eps Difference
0
Earnings History > 9 > surprise Percent
-
Earnings History > 10 > period
2022-03-31
Earnings History > 10 > report Date
2022-04-01
Earnings History > 10 > date
2022-03-31
Earnings History > 10 > before After Market
-
Earnings History > 10 > currency
USD
Earnings History > 10 > eps Actual
0.25
Earnings History > 10 > eps Estimate
-
Earnings History > 10 > eps Difference
0
Earnings History > 10 > surprise Percent
-
Earnings History > 11 > period
2021-12-31
Earnings History > 11 > report Date
2021-12-31
Earnings History > 11 > date
2021-12-31
Earnings History > 11 > before After Market
-
Earnings History > 11 > currency
USD
Earnings History > 11 > eps Actual
152.0203
Earnings History > 11 > eps Estimate
-
Earnings History > 11 > eps Difference
0
Earnings History > 11 > surprise Percent
-
Earnings History > 12 > period
2021-09-30
Earnings History > 12 > report Date
2021-10-21
Earnings History > 12 > date
2021-09-30
Earnings History > 12 > before After Market
-
Earnings History > 12 > currency
-
Earnings History > 12 > eps Actual
0.25
Earnings History > 12 > eps Estimate
0
Earnings History > 12 > eps Difference
0.25
Earnings History > 12 > surprise Percent
-
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company has a strategic collaboration with PsyLabs to produce Ibogaine. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/APsyence Biomedical sets Jan. 20 as effective date for reverse stock split MSN
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Psyence Biomedical Ltd. Common Shares
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
—
EPS Estimate
—
Date
2025-09-30
EPS Actual
-0.51
EPS Estimate
0
EPS Difference
-0.51
Surprise Percent
0%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.